Strategies of Tumor Immune Evasion

  title={Strategies of Tumor Immune Evasion},
  author={Barbara Seliger},
During the last decade, increased understanding of the molecular mechanisms responsible for immune activation to protect against challenges by tumor cells has revolutionized the field of immunotherapy research. It has been demonstrated that the dysfunction of the host’s immune system represents one of the major mechanisms by which tumors evade immunosurveillance. This is due, for example, to T cell anergy, the existence of regulatory T cells, and systemic defects of dendritic cells derived from… 
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
This review focuses on the specific signaling pathways through which TAMs involve in tumor antigen recognition disorders, recruitment and function of immunosuppressive cells, secretion of immunOSuppressive cytokines, crosstalk with immune checkpoints and formation of immune privileged sites.
Tumor Associated Immune Dysfunction: Immune Cells Involved and Suggested Therapies
The role of immune cells that support tumor growth are discussed and some immunotherapeutic strategies that may increase tumor immunogenicity and improve immunotherapy are suggested.
Immunomodulation and Genomic Instability
The focus of this chapter is the influence of genomic instability on the pro- and anti-tumor immune activities that impact on cancer development at multiple stages of progression.
Adaptive Immunity Does Not Strongly Suppress Spontaneous Tumors in a Sleeping Beauty Model of Cancer
Results indicate that B and T cells function to shape the genetic profile of tumors in various tumor types, despite being ineffective at clearing SB-induced tumors.
Cancer vaccine development: designing tumor cells for greater immunogenicity.
These immunotherapies are discussed as well as a feasible and efficient alternative that, in pre-clinical animal models, allows for the expression of specific immunostimulatory molecules on the surface of tumor cells by a novel protein transfer technology.
DNA Vaccination: Using the Patient's Immune System to Overcome Cancer
Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future.
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies
Oncolytic viruses have the added benefit of being directly cytolytic to cancer cells and thus promote antigen recognition within a highly immune-stimulating tumour microenvironment, which complicates their use upon previous exposure.
The Role of the Innate Immune System in Cancer Dormancy and Relapse
Identifying how immune cells interact with cancer cells at each step of cancer progression will pave the way for new therapies that target the reactivation of dormant cancer cells into recurrent, metastatic cancers.
Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response
The oncolytic properties of Canine Parvovirus (CPV or CPV2), the structure of the NS1 protein, the mechanism of on colytic action as well as role in inducing an antitumor immune response in different tumor models are discussed.
The role of regulatory T lymphocytes in immune control of MC-2 fibrosarcoma
It is found that splenocytes of both control and Treg depleted tumor bearing mice strongly but differently inhibited growth of tumor cells in vitro, and upon i.v. injecting specific monoclonal anti-Treg antibodies immediately prior to tumor cell intracutaneous transplantation, the tumor was rejected after initial growth.


Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
  • M. Mapara, M. Sykes
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Approaches to exploiting this beneficial effect without the deleterious consequence of graft-versus-host disease in allogeneic hematopoietic cell recipients are discussed.
Effective immunotherapy against cancer
A review discusses some of the salient issues that still need to be resolved in immunotherapy, focusing on the role of oxidative stress and the use of antioxidants to alleviate the immune hyporesponsiveness induced by reactive oxygen species (ROS).
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
This review will focus on the T-cell co-stimulatory molecule CTLA4, which has entered clinical trials and demonstrated objective clinical responses, initially for metastatic melanoma and has been associated with organ-specific inflammatory adverse events.
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
It is demonstrated here that T-cell–specific blockade of TGF-β signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells.
T-cell-directed cancer vaccines: the melanoma model
Using melanoma as the standard model for immunotherapy, various methods of T-cell-directed vaccination, the monitoring and analysis of the resulting immune response, and several clinical trials in which cancer vaccines have successfully induced immunisation are reviewed.
Breaking tolerance in cancer immunotherapy: time to ACT.
  • W. Overwijk
  • Biology, Medicine
    Current opinion in immunology
  • 2005
The use of dendritic cells in cancer immunotherapy.
Mechanisms and functional significance of tumour-induced dendritic-cell defects
This article focuses on the functional consequences and recently described mechanisms of the dendritic-cell defects in cancer.
Cellular immunotherapy: antigen recognition is just the beginning
Broad-scale immune monitoring, particularly high-throughput ex vivo analysis of human immune responses, promises to determine what comprises an effective immunotherapy and will lead to more sophisticated clinical trials, earlier determination of efficacy and individualized protocols.